£20m placing to accelerate Parsortix opportunities
Update | 28 June 2021
ANGLE has raised £20m (gross) to maintain momentum in consolidating its position as the leading player in CTC liquid biopsy. Its proprietary Parsortix microfluidic device captures circulating tumour cells (CTCs) for analysis and can complement ctDNA (circulating tumour DNA) liquid biopsies. New monies boost pro forma cash to c £47m supporting current initiatives (eg breast and ovarian cancer), new opportunities to expand Parsortix’s utility, and expanding the commercial infrastructure. ANGLE has identified two specific, highly commercially attractive opportunities: an LDT to assess prostate cancer risk, and a PD-L1 pharma services assay for clinical trials. Both would be offered through its two clinical laboratories (UK and US), which in addition to accelerating Parsortix system adoption, also act as demonstrators of how it enables targeted treatments, response monitoring, and improved patient outcomes. Our updated DCF-based model generates a valuation of £570m ($741m), or 244p/share.
|Year-end: December 31||2019*||2020||2021E||2022E|
|Adj. PBT (£m)||(9.1)||(13.8)||(20.5)||(19.2)|
|Net Income (£m)||(7.9)||(11.6)||(18.2)||(17.3)|
|Adj. EPS (p)||(4.7)||(6.7)||(7.7)||(7.3)|
28 June 2021
|Shares in issue||233.1m|
|12 month range||37.2-143.9p|
|Other exchanges||OTC QX|
ANGLE is a specialist diagnostics company. Its proprietary Parsortix technology can capture and harvest very rare cells, including CTCs (circulating tumour cells), from a blood sample. The FDA approval for its clinical use to guide precision cancer care will open up further multiple commercial opportunities.
+44 (0) 20 3637 5043
+44 (0) 20 3637 5041
Table of Contents
ANGLE’s £20m (gross) raise provides additional funds to expand and accelerate its product-led commercialisation initiatives for its Parsortix circulating tumour cell (CTC) liquid biopsy platform. Potential FDA clearance in H221 for Parsortix as a medical device for harvesting of CTCs for subsequent analysis in metastatic breast cancer (mBC) would be a key milestone for the company. This would be the first approval for a CTC harvesting system and only the third product authorisation for any liquid biopsy. While many investors are focused on this catalyst, it is only one facet of ANGLE’s myriad opportunities: the pharma services business is already generating strong interest and the first launch of an LDT (Laboratory Developed Test) from the newly established clinical services laboratories in the US and UK should happen in late-2021. The first pharma services contract was announced in April, and the PD-L1 assay (plus additional assays in development) will bolster this offering. LDT development for ovarian cancer is late-stage (data in Q421) and will shortly be underway for prostate cancer. Increasing visibility on ANGLE’s commercial plans should unlock further material value. Updating our DCF-based model for the raise results in a £570m valuation, equivalent to 244p per share.
The equity raise boosts pro forma funds to c £47.6m providing ANGLE with the resources to maintain commercialisation momentum with the Parsortix system in existing, already planned, and new applications. The company raised £20m (gross) from new and existing UK and US investors via the placing of 17.24m new shares at a price of 116p/share (6.83% discount to mid-market close on 23 June 2021). The new shares will be admitted to trading on 1 July.
Updating our valuation for the new funds raised and new shares issued generates a company valuation of £570m, equivalent to 244p per share, vs £549m or 255p per share previously. We continue to value ANGLE using a three-stage DCF based on comprehensive forecast cash flows to 2031, followed by a ten-year trending period, and a modest 2.5% terminal growth rate. We separately forecast cash flows for three business lines (research use, pharma services and LDTs, and clinical products) which are summed and netted against the central operating costs and current net cash/debt. Our May 2021 Initiation provides additional detail on our valuation methodology and outputs.
ANGLE is targeting four commercial revenue streams with the Parsortix system: research use; pharma services (CTC analysis in clinical trials); laboratory developed tests (LDTs) through its clinical laboratories; and clinical products (including through partners). New funds will address the latter three, providing additional resources for investment in R&D and into the sales and marketing infrastructure from H221 through FY22 and beyond.
As the US is the largest market for liquid biopsy by potential value it will be the initial launch market for many of ANGLE’s products. The company is therefore seeking to strengthen and develop its market position through several US key management hires. This larger experienced team is expected to have a significant impact on securing potential new pharma services contracts, corporate partners, and, once clearance is granted, driving adoption of LDTs and clinical products.
The establishment of its own CLIA and ISO-accredited clinical laboratories (accreditation expected in Q421) in the US and UK allows ANGLE to have direct control over several of its commercialisation activities. The two laboratories offer CTC analysis services to pharma companies and will, following relevant approvals, also launch LDTs (such as the triage LDTs for ovarian cancer and later for prostate cancer) that will be run at these locations. In addition to generating near-term revenues, these laboratories act as demonstrators of Parsortix’s clinical utility and accelerators of market awareness and adoption.
Proceeds from the June fundraise has been earmarked as follows:
We have not yet adjusted our FY21 and FY22 forecasts to reflect additional spend associated with the fund raise but intend to do so following greater clarity on the specific development plans. We anticipate that this would be provided at H121 interim results.
The Parsortix system has a broad potential clinical applicability and liquid biopsy is expected to be employed increasingly not only in initial diagnosis, but to monitor and guide treatment of cancer patients. It has numerous benefits over tissue biopsy, particularly when accessing primary or metastatic tumour sites is difficult, and in tracking changes of tumour status over time. A substantial portion of the equity raise – £7m – will be directed to pursuing a major new opportunity for Parsortix in prostate cancer screening.
ANGLE is seeking to develop a prostate cancer triage test which would evaluate men with elevated PSA (prostate-specific antigen) to determine whether (a) they do have prostate cancer (PC) and if so (b) assess the aggressiveness of the disease (c 90% of cases are benign or indolent). This would reduce the need for expensive (typically c $2k) and invasive core tissue biopsy which, despite being the current gold standard for diagnosis, detects cancer in only c 25% of biopsies reflecting ‘overuse’ (but also routinely missing some incidences of PC) and is associated with a high risk of complications.
A pilot study run by Barts Cancer Institute, published in Clinical Cancer Research, has shown supportive evidence that CTCs can be used to detect the presence of PC and also risk stratify patients for intervention or further surveillance. The Barts study in 81 prostate cancer patients (34 with castrate-resistant PC and 38 localised PC) found CTCs in all CRPC cases and in 79% of localised patients.
Given the parallels with the ovarian cancer triage test, we expect that the PC development pathway could take a similar route as an LDT. The initial step would be an assay development study in a relatively small number of patients (c 200), which could support LDT launch in 2023. Pursuit of an approval as a clinical product would require a larger clinical verification study. We anticipate that management will provide future details and guidance on the timing and design of the PC development pathway which would determine the phasing of R&D investment and potential launch timings.
The commercial opportunity is sizeable, with similar application characteristics to those in other difficult to biopsy solid tumours. These can be classified as high-risk screening, active surveillance, therapeutic decision making, and remission monitoring. Management estimates the addressable markets in the US alone as being worth $1.20bn, $1.47bn, $3.07bn, and $0.99bn respectively. The first of these tests could be ready for commercial launch as soon as end-2022, with further roll outs through to 2024.
Prostate cancer adds a fourth dimension to the three priority addressable markets previously highlighted by ANGLE. Each of these has new funds directed towards supporting future marketing plans, and are covered in more detail, along with their markets, in our May 2021 Initiation. To recap, these are:
The PD-L1 assay, known as Portrait Plus PD-L1, is the second pharma services test offered by ANGLE, the first being the Epithelial/Mesenchymal Transition (EMT) enumeration and CTC cluster assay, known as Portrait Plus. Tumour PD-L1 status is critical to determining the appropriate immunotherapy regimen and, for clinical trials it offers key information for the assessment of drug effectiveness and may enable the development of companion diagnostics to select patients likely to respond to the drugs under evaluation. Use of ANGLE’s Portrait Plus PD-L1 assay in Phase I studies by pharmaceutical development companies or CROs is a precursor to involvement in the later clinical stages where patient numbers are larger and trials longer.
ANGLE has a significant opportunity in developing additional assays for harvested CTCs, and £2m of new funds will be invested in this. As well as bespoke assay development for customers, new biomarker-based tests – including those where ctDNA-based liquid biopsies are not applicable as the biomarker is protein – could contribute to an expanded menu of assays that can be offered direct to pharma clients or used in LDTs.
FDA device clearance of Parsortix for harvesting of CTCs for subsequent analysis in mBC will provide major validation for ANGLE. The de novo submission was filed in September 2020, provision of the response to a subsequent AIR (Additional Information Request) was announced in June 2021 and, assuming no delays, clearance is possible in H221. This could be the catalyst for Parsortix partnerships with a wider and larger number of organisations, as well as permitting sale of the mBC test as a clinical product to guide treatment decisions.
Liquid biopsy has an important role to play in mBC, particularly as many metastatic sites are not suitable for routine (and regular) biopsy and that the biomarkers currently examined (eg oestrogen, progesterone, and HER2) may alter during disease progression/treatment, and thus not provide a sufficiently complete picture of a tumour’s current sensitivities to direct effective treatment.
A LDT to triage abnormal pelvic masses is the initial Parsortix application in ovarian cancer. It has the potential to be a best-in-class test for discriminating between benign pelvic masses and ovarian cancer and informing next surgical steps. ANGLE plans to launch an ovarian cancer LDT in late-2021 following release of Q421 top line clinical verification study data.
The ovarian cancer triage LDT will initially be available to private payers via clinicians. Data generated will be leveraged to obtain reimbursement codes for Parsortix clinical applications. Subject to supportive clinical verification studies, this LDT could also be applied to monitoring in watchful waiting (of pre-surgical pelvic masses) or for disease remission monitoring.
Trinity Delta Research Limited (“TDRL”; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited (“ED”). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.
ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.
In the preparation of this report TDRL has used publicly available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.
Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves (‘issuer financed research’) and as such is not deemed to be independent, as defined by the FCA, but is ‘objective’ in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.
This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at www.fisma.org. TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.
Copyright 2021 Trinity Delta Research Limited. All rights reserved.